Novel therapeutic for H. pylori infections
H. pylori is a bacterium residing in the stomach causing peptic ulcers, and gastric cancer.
More than 50% of the population is infected with H. pylori, while the WHO considers H. pylori one of the highest priority pathogens.
H pylori infections are currently treated with a combination of antibiotics and proton pump inhibitors (PPIs). However, such treatments are compromised by the rapid emergence of antibiotic-resistant H. pylori strains, contribute to global antibiotic resistance epidemic, and have side effects primarily dysbiosis. In addition, prolonged PPI intake is reported to have a two-fold risk increase for gastric cancer development.
As a key first step in the H pylori infection is adhesion of the bacterium to the gastric mucosa, AVVA pharmaceutics is developing a drug that prevents this critical first step in the process of infections. The anti adhesion therapy is an alternative effective treatment without the need of antibiotics, does not contribute to antibiotic resistance, and can potentially achieve higher eradication rates in combination with antibiotics.
The project is currently in the in vivo proof of concept stage.
Lefteris Zacharia, MBA, PhD
AVVA Pharmaceuticals Ltd.